Table 2.
The heterogeneity analysis by Cochran’s Q test and horizontal Pleiotropy analysis by MR-Egger regression.
| Outcome | Exposure | Heterogeneity (IVW) | Pleiotropy | |||
|---|---|---|---|---|---|---|
| Q | Q_pval | MR-Egger Intercept | P value | |||
| DLBCL | T2D | 103.58 | 0.73 | -0.0014 | 0.9 | |
| Obesity | 4.19 | 0.76 | -0.0117 | 0.85 | ||
| dHypo | 7.39 | 0.19 | 0.048 | 0.37 | ||
| HPL | 19.81 | 0.14 | -0.0248 | 0.56 | ||
| HTH | 12.81 | 0.17 | -0.126 | 0.05 | ||
| LL | T2D | 125.86 | 0.18 | 0 | 0.08 | |
| Obesity | 1.67 | 0.95 | 0.0001 | 0.65 | ||
| dHypo | 10.43 | 0.11 | -0.0002 | 0.11 | ||
| HPL | 9.39 | 0.81 | 0 | 0.94 | ||
| HTH | 7.34 | 0.6 | 0 | 0.31 | ||
| FL | T2D | 103.25 | 0.76 | -0.0161 | 0.35 | |
| Obesity | 4.7 | 0.58 | 0.1195 | 0.36 | ||
| dHypo | 6.78 | 0.24 | 0.142 | 0.1 | ||
| HPL | 11.43 | 0.57 | 0.0032 | 0.95 | ||
| HTH | 17.49 | 0.06 | 0.036 | 0.67 | ||
| NHL | T2D | 132.42 | 0.11 | 0.0018 | 0.82 | |
| Obesity | 8.01 | 0.24 | 0.0667 | 0.31 | ||
| dHypo | 12.36 | 0.05 | -0.0054 | 0.9 | ||
| HPL | 7.3 | 0.92 | 0.029 | 0.21 | ||
| HTH | 77.53 | 0 | -0.164 | 0.1 | ||
| Lymph node tumor | T2D | 135.56 | 0.08 | 0.0029 | 0.82 | |
| Obesity | 7.53 | 0.27 | -0.0388 | 0.7 | ||
| dHypo | 3.51 | 0.62 | -0.0161 | 0.73 | ||
| HPL | 11.61 | 0.56 | -0.0082 | 0.81 | ||
| HTH | 5.53 | 0.9 | -0.0258 | 0.52 | ||
IVW, inverse variance weighted; DLBCL, Diffuse Large B-Cell Lymphoma; LL, Lymphocytic Leukemia; FL, Follicular Lymphoma; NHL, Non-Hodgkin’s Lymphoma; T2D, type 2 diabetes; dHypo, diabetic hypoglycemia; HPL, hyperlipidemia; HTH, hyperthyroidism.